Grant of Restricted Stock Units and Warrants to Employees in Genmab
21 nov. 2024 14h48 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; November 21, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 10,273 restricted stock units and 10,853 warrants to employees...
Genmab Announces Financial Results for the First Nine Months of 2024
06 nov. 2024 11h02 HE
|
Genmab A/S
November 6, 2024 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2024 Highlights European Commission (EC) granted conditional marketing authorization for TEPKINLY®...
Genmab to Present at Jefferies London Healthcare Conference
05 nov. 2024 13h11 HE
|
Genmab A/S
Media ReleaseCOPENHAGEN, Denmark; November 5, 2024 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer, Jan van de Winkel, Ph.D. and Chief Financial Officer, Anthony...
Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting
05 nov. 2024 12h00 HE
|
Genmab A/S
Media ReleaseCOPENHAGEN, Denmark; November 5, 2024 More than 20 abstracts, including four oral presentations, with new clinical data across lines of therapy and subgroups of non-Hodgkin’s lymphoma...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024
15 oct. 2024 06h25 HE
|
Genmab A/S
Company Announcement Net sales of DARZALEX® in the third quarter of 2024 totaled USD 3,016 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) ...
Major Shareholder Announcement
04 oct. 2024 13h55 HE
|
Genmab A/S
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; October 4, 2024 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital...
Grant of Restricted Stock Units and Warrants to Employees in Genmab
26 sept. 2024 15h17 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; September 26, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 23,954 restricted stock units and 13,915 warrants to employees...
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
15 sept. 2024 08h45 HE
|
Genmab A/S
Media ReleaseCOPENHAGEN, Denmark; September 15, 2024 Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate in heavily pretreated patients with ovarian cancer in dose expansion...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
10 sept. 2024 16h06 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; September 10, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 11,729 shares as a consequence of the exercise of employee warrants. The...
Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
26 août 2024 12h26 HE
|
Genmab A/S
Media ReleaseCOPENHAGEN, Denmark; August 26, 2024 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan van de Winkel, Ph.D. and Chief Financial Officer Anthony Pagano will...